The early detection of bladder cancer results in less invasive treatment with cure rates of 90% with long term survival Published on 23/05/2024 This is the fifth most commonly diagnosed tumour in Spain, with an incidence almost five times greater in men than in women.
La investigación de biomarcadores en cáncer de vejiga optimiza la selección de pacientes candidatos a inmunoterapia Published on 23/09/2022 Un estudio, donde participa MD Anderson Cancer Center Madrid – Hospiten, muestra que la selección más certera de los pacientes que responderán a la inmunoterapia podría reducir los niveles de toxicidad, al evitar la administración de fármacos con reducidas probabilidades de éxito
The construction of a neobladder, a solution used in 90% of bladder cancer operations at MD Anderson Madrid – Hospiten Published on 09/05/2022 Multidisciplinary management and rapid access to innovative therapies maximize the chances of cure and recovery for patients with bladder cancer
A combination of chemotherapy and immunotherapy for the first time shows superiority over chemotherapy alone in metastatic bladder cancer Published on 08/10/2019 Dr. Enrique Grande, head of the Medical Oncology Service at MD Anderson Madrid – Hospiten, is co-chair of the IMvigor130 clinical trial, which has evaluated the efficacy of this combination in front line treatment
MD Anderson Cancer Center Madrid – Hospiten and emov join forces to build awareness among the public in Madrid of the effects of airborne pollution on the health Published on 15/11/2018 Published November 15 2018